Skip to main content
. 2020 Dec 9;100(19):5946. doi: 10.2340/00015555-3700

Fig. 1.

Fig. 1

Static Physician’s Global Assessment (sPGA) and patient global assessments (PtGA) among patients with psoriasis treated with ixekizumab (IXE) or ustekinumab (UST) for 52 weeks. PtGA: p < 0.01, p < 0.001 UST vs IXE; sPGA: **p < 0.01, ***p < 0.001 UST vs IXE. p-values derived from Wilcoxon rank sum test. mBOCF: modified baseline-observation carried forward.